Sign in

Schizophrenia Journal

@schizjournal.bsky.social
122 followers 190 following 53 posts

Schizophrenia is a high-quality Springer Nature journal published in partnership with the Schizophrenia Research Society (SIRS) @SIRSGlobal nature.com/npjschz/

PostsRepliesMedia
Schizophrenia Journal @schizjournal.bsky.social · 04/10/2026
New findings point to a more complex, and more dorsally localized, neural basis of aberrant salience than previously assumed 👇 @sirsofficial.bsky.social nature.com/articles/s41537-026-00795-2
nature.com
Aberrant salience is selectively associated with ventral midbrain connectivity to the dorsal but not ventral striatum - Schizophrenia
Schizophrenia - Aberrant salience is selectively associated with ventral midbrain connectivity to the dorsal but not ventral striatum
000
Schizophrenia Journal @schizjournal.bsky.social · 18/09/2026
New research: In psychosis, higher default mode network connectivity was associated with greater odds of tobacco use—highlighting a potential brain-based target for tobacco-dependence treatment. @sirsofficial.bsky.social Read the article: nature.com/articles/s41537-026-00797-0
nature.com
Parietal default mode network connectivity is associated with tobacco use in psychosis - Schizophrenia
Schizophrenia - Parietal default mode network connectivity is associated with tobacco use in psychosis
000
Reposted by Schizophrenia Journal
Schizophrenia International Research Society (SIRS) @sirsofficial.bsky.social · 08/09/2026
🎥 SIRS is looking for short documentaries and videos for a special digital media exhibition at the 2027 Annual Congress in Montréal, Canada! 🔗 Submit your project here: sirs.societyconference.com/user/?conf_i...
012
Reposted by Schizophrenia Journal
Schizophrenia International Research Society (SIRS) @sirsofficial.bsky.social · 10/09/2026
🏆Help us recognize SIRS members making outstanding contributions to schizophrenia research, leadership, service, and global impact. 🌍🔬 📅 Deadline: December 1, 2026 Explore all award categories and apply: schizophreniaresearchsociety.org/meetings/awa...
022
Schizophrenia Journal @schizjournal.bsky.social · 14/09/2026
New study in @schizjournal uses network analysis of PANSS data from 1,213 participants to support a five-dimensional symptom structure, and identifies potential "bridge symptoms" linking domains @sirsofficial.bsky.social Read more: nature.com/articles/s41537-026-00799-y
nature.com
Revisiting symptom dimensions in schizophrenia with exploratory graph analysis - Schizophrenia
Schizophrenia - Revisiting symptom dimensions in schizophrenia with exploratory graph analysis
000
Schizophrenia Journal @schizjournal.bsky.social · 29/08/2026
New paper: Speech analytics can reliably capture negative symptom severity in schizophrenia. Speech proportion, speech rate, and unfilled pauses emerged as robust, clinically relevant digital markers across visits and tasks. @sirsofficial.bsky.social 🔗 nature.com/articles/s41537-026-00788-1
nature.com
Identification of robust speech-based markers of negative symptom severity in schizophrenia spectrum disorders - Schizophrenia
Schizophrenia - Identification of robust speech-based markers of negative symptom severity in schizophrenia spectrum disorders
010
Schizophrenia Journal @schizjournal.bsky.social · 24/08/2026
New study: Schizophrenia: temporal imprecision in phase, time, and frequency domains Using MEG, Kholghi & Northoff show convergent temporal imprecision across phase, time and frequency in first-episode schizophrenia, linked to reduced mismatch negativity nature.com/articles/s41537-026-00792-5
nature.com
Schizophrenia: temporal imprecision in phase, time, and frequency domains - Schizophrenia
Schizophrenia - Schizophrenia: temporal imprecision in phase, time, and frequency domains
010
Schizophrenia Journal @schizjournal.bsky.social · 21/08/2026
New systematic review: How well do current high-risk criteria actually predict transition to psychosis among real-world help-seeking populations? @sirsofficial.bsky.social Read the full article here 👇 nature.com/articles/s41537-026-00785-4
nature.com
Discriminative validity of Clinical High-Risk Status for Psychosis among help-seekers: a systematic review and meta-analysis - Schizophrenia
Schizophrenia - Discriminative validity of Clinical High-Risk Status for Psychosis among help-seekers: a systematic review and meta-analysis
010
Schizophrenia Journal @schizjournal.bsky.social · 18/08/2026
Key finding: Comparable retention: There were no significant differences in drop-out rates between the EBPI and non-EBPI groups.
000
Schizophrenia Journal @schizjournal.bsky.social · 18/08/2026
Key finding: Robust clinical stabilization with LAI: Both groups improved in core symptom domains, supporting the effectiveness of LAI antipsychotics for clinical stabilization in early-phase schizophrenia.
100
Schizophrenia Journal @schizjournal.bsky.social · 18/08/2026
Key findings: Functional gains with EBPI: Participants who received EBPI showed greater improvements in real-world psychosocial functioning over time, with significant advantages at 12 months follow-up and across all assessment points.
100
Schizophrenia Journal @schizjournal.bsky.social · 18/08/2026
Key finding: Limited use of EBPI: Only 37% of participants received at least one EBPI, indicating that dissemination in routine practice remains modest.
100
Schizophrenia Journal @schizjournal.bsky.social · 18/08/2026
New prospective study published in @schizjournal examine how Evidence-Based Psychosocial Interventions (EBPI) are implemented in real-world practice and how they impact outcomes in individuals with early-phase schizophrenia who are stabilized on long-acting injectable LAIs.
100
Schizophrenia Journal @schizjournal.bsky.social · 18/08/2026
💫How to move beyond symptom stabilization to improve everyday functioning in early phases of schizophrenia? New study examine how Evidence Based Psychosocial Interventions are implemented in real-world practice @sirsofficial.bsky.social nature.com/articles/s41537-026-00791-6
nature.com
Evidence-based psychosocial interventions in recent-onset schizophrenia treated with long-acting injectable antipsychotics: a real-world prospective multicenter study - Schizophrenia
Schizophrenia - Evidence-based psychosocial interventions in recent-onset schizophrenia treated with long-acting injectable antipsychotics: a real-world prospective multicenter study
110
Schizophrenia Journal @schizjournal.bsky.social · 17/08/2026
We are looking forward to the 2027 SIRS Annual Congress in Montréal, Canada, 10–14 April 2027!
020
Schizophrenia Journal @schizjournal.bsky.social · 04/08/2026
@springernature.com
000
Schizophrenia Journal @schizjournal.bsky.social · 04/08/2026
The study supports partially distinct, and sex-specific, genetic and developmental mechanisms linking perceived loneliness and objective social isolation to psychosis risk. It highlights adolescent loneliness as a potential target for early preventive interventions.
000
Schizophrenia Journal @schizjournal.bsky.social · 04/08/2026
Using data from the EU-GEI study (2045 first‑episode psychosis patients and 2456 controls), this work examines how PGS for loneliness and isolation-related traits relate to psychosis diagnoses, symptom dimensions, and developmental experiences of loneliness & social isolation.
100
Schizophrenia Journal @schizjournal.bsky.social · 04/08/2026
Social isolation and loneliness are consistently associated with schizophrenia, yet their distinct genetic contributions and developmental pathways across the psychosis spectrum remain unclear.
100
Schizophrenia Journal @schizjournal.bsky.social · 04/08/2026
New in @schizjournal.bsky.social: Polygenic liability to loneliness is associated with increased psychosis risk, partly through adolescent loneliness, with sex-specific patterns @sirsofficial.bsky.social nature.com/articles/s41537-026-00787-2
nature.com
Polygenic liability to loneliness increases psychosis risk through adolescent loneliness: evidence from the EU-GEI study - Schizophrenia
Schizophrenia - Polygenic liability to loneliness increases psychosis risk through adolescent loneliness: evidence from the EU-GEI study
210
Schizophrenia Journal @schizjournal.bsky.social · 19/06/2026
New in @schizjournal.bsky.social: A pseudogene-mitochondria link in schizophrenia New study reports that the pseudogene NDUFV2P1 disrupts nuclear export of NDUFV2 mRNA, impairing complex-I function and mitochondrial energy metabolism @sirsofficial.bsky.social Read more ⬇️ bit.ly/44jCa8T
bit.ly
A new mechanism underlying mitochondrial dysfunction in schizophrenia – attenuated mRNA transport of the complex I subunit NDUFV2 by its pseudogene NDUFV2P1 - Schizophrenia
Schizophrenia - A new mechanism underlying mitochondrial dysfunction in schizophrenia – attenuated mRNA transport of the complex I subunit NDUFV2 by its pseudogene NDUFV2P1
010
Schizophrenia Journal @schizjournal.bsky.social · 16/06/2026
New paper in @schizjournal.bsky.social investigating🧬Inflammation, endothelial function, and extracellular matrix pathways in first-episode drug-naïve schizophrenia www.nature.com/articles/s41537-026-00766-7 @sirsofficial.bsky.social
nature.com
Integrated alterations in inflammation, endothelial function, and extracellular matrix pathways in first-episode drug-naïve schizophrenia - Schizophrenia
Schizophrenia - Integrated alterations in inflammation, endothelial function, and extracellular matrix pathways in first-episode drug-naïve schizophrenia
000
Schizophrenia Journal @schizjournal.bsky.social · 22/05/2026
Announcing a New Article Collection: Neuroimaging Biomarkers in Psychotic Disorders - open for submissions until 24 November 2026! @sirsofficial.bsky.social www.nature.com/collections/...
nature.com
Neuroimaging Biomarkers in Psychotic Disorders
Focusing on structural and functional brain changes linked to symptoms and cognition, this collection aims to accelerate translational pipelines for early ...
000
Schizophrenia Journal @schizjournal.bsky.social · 21/05/2026
Congratulations to our editor Anthony Grace, who recieved the SIRS Distinguished Service Award! @sirsofficial.bsky.social
020
Schizophrenia Journal @schizjournal.bsky.social · 20/05/2026
Announcing a New Article Collection: Machine Learning in Early Psychosis Prediction - open for submissions until 27 November 2026! @sirsofficial.bsky.social www.nature.com/collections/...
nature.com
Machine Learning in Early Psychosis Prediction
This collection aims to showcase studies that harness computational algorithms to forecast the emergence or course of psychosis. It aims to publish ...
031
Schizophrenia Journal @schizjournal.bsky.social · 18/12/2025
New Article Collection on Antipsychotic Discontinuation! This new series of papers explores whether dose reduction or withdrawal is advisable and the risks associated with such a procedure. @sirsofficial.bsky.social Collection: go.nature.com/4pS4EA2
go.nature.com
Antipsychotic Discontinuation
Antipsychotic medications have revolutionized the treatment of schizophrenia. However, the D2 antagonist antipsychotic medications, while effective, are still ...
021
Reposted by Schizophrenia Journal
Schizophrenia International Research Society (SIRS) @sirsofficial.bsky.social · 12/11/2025
🏛 SIRS 2026 Elections – Nominations Open! We’re accepting nominations for: ✨ President-Elect ✨ Board Members (6 positions) ✨ Junior Board Members (3 positions) Help shape the Society’s future. 🗓 Deadline: 28 November 2025 🔗: sirs.societyconference.com?conf_id=1002... #SIRS2026
021
Schizophrenia Journal @schizjournal.bsky.social · 09/11/2025
👉New Article Collection! We are proud to highlight our new article collection, Pathways to prevention: background and methodology for the Accelerating Medicines Partnership® Schizophrenia Program @sirsofficial.bsky.social go.nature.com/495Z3Av
go.nature.com
Pathways to prevention: background and methodology for the Accelerating Medicines Partnership® Schizophrenia Program
The discovery of antipsychotic drugs for the treatment of schizophrenia has reshaped the landscape for the ability to treat this devastating disorder. ...
022
Reposted by Schizophrenia Journal
Schizophrenia International Research Society (SIRS) @sirsofficial.bsky.social · 15/10/2025
Schizophrenia isn’t just in the brain. 🧠💔🦴 New study (Xie et al., 2025, Schizophrenia) maps shared genetic links between SCZ and heart, bone & abdominal organ imaging traits—revealing its truly systemic nature and new therapeutic targets. 🔗 www.nature.com/articles/s41...
053
Reposted by Schizophrenia Journal
Schizophrenia International Research Society (SIRS) @sirsofficial.bsky.social · 24/10/2025
New research explores how childhood trauma and violence intersect in schizophrenia. Reduced connectivity between the orbitofrontal & temporal brain regions mediates this link—potential neural targets for trauma-related interventions. 🔗 www.nature.com/articles/s41...
021
Reposted by Schizophrenia Journal
Schizophrenia International Research Society (SIRS) @sirsofficial.bsky.social · 28/10/2025
In Clinical High Risk research, how participants are recruited matters. Recruitment sources influence sex, age, and clinical profiles, shaping the heterogeneity seen across CHR studies. Accounting for these differences is crucial when interpreting findings. 🔗 Article: www.nature.com/articles/s41...
031
Schizophrenia Journal @schizjournal.bsky.social · 14/10/2025
New review addressing the knowledge gap between voice hearing in psychosis and perceptual experiences in other sensory modalities with overview of voices and altered perceptual experiences across psychotic, mood and anxiety disorders @sirsofficial.bsky.social bit.ly/3J5ibDW
bit.ly
Hearing voices and other altered perceptual experiences across psychotic, mood, and anxiety disorders: from phenomenology and mechanisms to future directions - Schizophrenia
Schizophrenia - Hearing voices and other altered perceptual experiences across psychotic, mood, and anxiety disorders: from phenomenology and mechanisms to future directions
052
Schizophrenia Journal @schizjournal.bsky.social · 03/10/2025
A New Chapter for Schizophrenia Journal... 📖
040
Schizophrenia Journal @schizjournal.bsky.social · 08/09/2025
New investigation of what lies behind the 17-year reduction in life expectancy gap between #schizophrenia patients and the general population. 2nd-gen antipsychotics and low frequency hospitalization were associated with reduced mortality @sirsofficial.bsky.social bit.ly/4gdulqF
bit.ly
What is behind the 17-year life expectancy gap between individuals with schizophrenia and the general population? - Schizophrenia
Schizophrenia - What is behind the 17-year life expectancy gap between individuals with schizophrenia and the general population?
021
Reposted by Schizophrenia Journal
Schizophrenia International Research Society (SIRS) @sirsofficial.bsky.social · 15/07/2025
💡 New Findings in Clozapine Pharmacokinetics 🔗 Read the study here: doi.org/10.1038/s415... #Clozapine #Pharmacokinetics #Inflammation #Schizophrenia
doi.org
Elevated neutrophil-to-lymphocyte ratios correlate with increased clozapine concentration-to-dose ratios during titration - Schizophrenia
Schizophrenia - Elevated neutrophil-to-lymphocyte ratios correlate with increased clozapine concentration-to-dose ratios during titration
001
Reposted by Schizophrenia Journal
Schizophrenia International Research Society (SIRS) @sirsofficial.bsky.social · 03/09/2025
📆 September is here! Your SIRS Submission Deadlines are Approaching FAST! Be Part of the Conversation in Florence, Italy Submit Your Symposia Proposal Today! #SIRS2026 LINK: sirs.societyconference.com/v2/#card/sub...
001
Schizophrenia Journal @schizjournal.bsky.social · 01/09/2025
This is one of the circuits which has been previously related to symptom improvements in patients with firstepisode of psychosis.
000
Schizophrenia Journal @schizjournal.bsky.social · 01/09/2025
The authors found that treatment-responsive and treatment-resistant psychosis groups differed in longitudinal changes in connectivity between ventral striatal and temporal cortical regions.
100
Schizophrenia Journal @schizjournal.bsky.social · 01/09/2025
New study found longitudinal changes in striatocortical connectivity in first-episode psychosis associated with the emergence of treatment resistance. @sirsofficial.bsky.social bit.ly/3JHvj26
bit.ly
Longitudinal changes in striatocortical connectivity in first-episode psychosis associated with the emergence of treatment resistance - Schizophrenia
Schizophrenia - Longitudinal changes in striatocortical connectivity in first-episode psychosis associated with the emergence of treatment resistance
111
Schizophrenia Journal @schizjournal.bsky.social · 11/07/2025
Link to video interview: vimeo.com/1060935583
vimeo.com
Schizophrenia Interview - Dr. Torous
This is "Schizophrenia Interview - Dr. Torous" by SIRS on Vimeo, the home for high quality videos and the people who love them.
000
Schizophrenia Journal @schizjournal.bsky.social · 11/07/2025
How can smartphone and wearable digital biomarkers inform about risk of developing schizophrenia? Learn more about the use of digital phenotyping in the #AMP_SZ study in this new paper #biomarkers @SIRSGlobal bit.ly/4kxW1qH
bit.ly
Digital health technologies in the accelerating medicines Partnership® Schizophrenia Program - Schizophrenia
Schizophrenia - Digital health technologies in the accelerating medicines Partnership® Schizophrenia Program
100
Schizophrenia Journal @schizjournal.bsky.social · 10/07/2025
Watch Dr. Perkins discuss their work and this article: vimeo.com/1062879582?s...
vimeo.com
Schizophrenia Interview - Dr. Perkins
This is "Schizophrenia Interview - Dr. Perkins" by SIRS on Vimeo, the home for high quality videos and the people who love them.
001
Schizophrenia Journal @schizjournal.bsky.social · 10/07/2025
Advances in proteomics & genomics are shedding light on biomarkers linked to schizophrenia risk. The AMP® Schizophrenia study is tracking 2,000+ participants to uncover blood & saliva markers that predict outcomes & reveal underlying biology. #Psychiatry #Biomarkers #AMP_SCZ bit.ly/3IB5Dn6
bit.ly
Body fluid biomarkers and psychosis risk in The Accelerating Medicines Partnership® Schizophrenia Program: design considerations - Schizophrenia
Schizophrenia - Body fluid biomarkers and psychosis risk in The Accelerating Medicines Partnership® Schizophrenia Program: design considerations
101
Schizophrenia Journal @schizjournal.bsky.social · 09/07/2025
Watch Dr Daniel H. Mathalon discuss their work and this article: vimeo.com/1066564687
vimeo.com
Schizophrenia Interview: Dr. Mathalon
This is "Schizophrenia Interview: Dr. Mathalon" by SIRS on Vimeo, the home for high quality videos and the people who love them.
001
Schizophrenia Journal @schizjournal.bsky.social · 09/07/2025
🚨 AMP SCZ EEG Study! 🧠⚡ CHR patients need better treatments. EEG biomarkers show strong reliability & potential for predicting outcomes, tracking illness, & guiding interventions #EEG bit.ly/46ungiw
bit.ly
The electroencephalography protocol for the Accelerating Medicines Partnership® Schizophrenia Program: Reliability and stability of measures - Schizophrenia
Schizophrenia - The electroencephalography protocol for the Accelerating Medicines Partnership® Schizophrenia Program: Reliability and stability of measures
101
Schizophrenia Journal @schizjournal.bsky.social · 02/05/2025
Curious about predicting clinical outcomes? New paper in @schizjournal.bsky.social special issue shows how multidisciplinary experts shaped the AMP #Schizophrenia analysis strategy. Explore key decisions & data-driven insights! @sirsofficial.bsky.social @NoraPenzel @poloscience go.nature.com/4lYwQzv
go.nature.com
Data analysis strategies for the Accelerating Medicines Partnership® Schizophrenia Program - Schizophrenia
Schizophrenia - Data analysis strategies for the Accelerating Medicines Partnership® Schizophrenia Program
012
Schizophrenia Journal @schizjournal.bsky.social · 23/04/2025
Watch the interview with Dr. Kapur @tkapur.bsky.social, Dr. Lewandowski, and Carlos Larrauri vimeo.com/1050068801
vimeo.com
Schizophrenia Interview with Dr. Kapur, Dr. Lewandowski, and Carlos Larrauri
This is "Schizophrenia Interview with Dr. Kapur, Dr. Lewandowski, and Carlos Larrauri" by SIRS on Vimeo, the home for high quality videos and the people…
002
Schizophrenia Journal @schizjournal.bsky.social · 23/04/2025
Getting lived experience to guide psychosis research: The AMP® SCZ program integrates voices of those with lived experience into every stage to foster trust, enhance research outcomes, and inform future strategies for treatment and prevention @sirsofficial.bsky.social go.nature.com/4lIGYfu
go.nature.com
Bridging Science and Hope: integrating and Communicating Lived experience in Accelerating Medicines Partnership® Schizophrenia Program - Schizophrenia
The Accelerating Medicines Partnership Schizophrenia (AMP® SCZ) program integrates lived experience into psychosis research, leveraging over three decades of foundational studies to improve research q...
112
Schizophrenia Journal @schizjournal.bsky.social · 21/04/2025
go.nature.com/4cHoQ1r
go.nature.com
Sample ascertainment and clinical outcome measures in the Accelerating Medicines Partnership® Schizophrenia Program - Schizophrenia
Schizophrenia - Sample ascertainment and clinical outcome measures in the Accelerating Medicines Partnership® Schizophrenia Program
011
Schizophrenia Journal @schizjournal.bsky.social · 21/04/2025
Dr Jean Addington discusses the challenges and highlights the most important aspects of the selection and application of clinical assessment and outcome measures in the large multisite AMP®SCZ study investigating CHR go.nature.com/4cHoQ1r @sirsofficial.bsky.social vimeo.com/1040425281
vimeo.com
Schizophrenia Interview with Dr. Addington
This is "Schizophrenia Interview with Dr. Addington" by SIRS on Vimeo, the home for high quality videos and the people who love them.
112